In a market shaped by aggressive volume-based procurement policies, where orthopedic device prices have dropped by over 60%, China's orthopedic surgery volume is still climbing at a double-digit pace.

Yet while precision medicine enables robotic systems to reach sub-millimeter accuracy, the industry faces a paradox: many companies are trapped in a cycle of scale without profitability.

The sector stands at an inflection point. The question is no longer about achieving technological breakthroughs, but rather: how can we turn them into scalable clinical value and compete globally beyond price?

At the inaugural Global Orthopedics Conference 2025 held in Beijing, MedChina sat down with Jianxun Liu, Senior VP of Great Robotics, to explore how the company is bridging innovation with impact—transforming from original research to clinical delivery, and from a China-based startup to a global contender.

From Lab to OR: Innovation Rooted in Clinical Impact

Founded in 2021, Great Robotics has quickly become a standout force in China’s surgical robotics space. At the conference, it received the 2025 Global Orthopedics Innovation Award for its next-generation embodied intelligence system: the NewDawn United platform.

This all-in-one AI-powered solution integrates:

• Medical imaging enhancement (Deepseek framework)

• Embodied intelligence for robotic adaptability

• Full-process surgical automation from diagnostics to post-op evaluation

Their flagship robotic platform, NewDawn Endo, fuses proprietary algorithms with large language model distillation and embodied AI to achieve:

• High-quality imaging under low radiation exposure

• Path optimization, real-time decision-making, and motion precision under complex surgical conditions

More than a surgical tool, NewDawn Endo is a full-stack intelligent operating system. It’s designed for versatility, first targeting spinal degenerative conditions but engineered to expand into endoscopic fusion and neurosurgical applications through modular end-effector development.

Already tested in hundreds of animal and cadaver cases, NewDawn Endo is currently undergoing multicenter clinical trials in collaboration with top institutions such as Qilu Hospital and PLA General Hospital.

Going Global: Clinical Value as a Strategic Advantage

As global competition in surgical robotics intensifies, Chinese companies like Great Robotics are stepping into the international spotlight—backed by national initiatives such as the Belt and Road.

The company has already conducted deep market studies in Central Asia, Southeast Asia, and Europe, securing ministerial-level engagements and multiple cooperation agreements.

With a domestically controllable supply chain, Great Robotics remains resilient against geopolitical uncertainties, an advantage as some U.S. players face rising import-export costs and component instability.

Open Ecosystem: A Different Playbook for Growth

In an industry plagued by “race-to-the-bottom” pricing and siloed development, Great Robotics has taken a radically different approach: open collaboration.

“We don’t believe innovation should be kept behind closed doors,” said Liu. “Like Siemens and Philips before us, we aim to uplift the entire ecosystem.”

Through ODM/OEM partnerships and modular tech sharing, the company is building an ecosystem across orthopedics and vascular intervention lines. Partners gain access to advanced systems, while Great Robotics benefits from broader clinical insights and shared development cycles.

This “shared progress” model enables the company to evolve faster—and keeps its innovation engine running.

Final Word: A Mission That Goes Beyond the Market

“As a new generation of medtech innovators, we’re not just building a business—we’re helping rewrite China’s role in global healthcare,” Liu reflected.

With a strong commitment to clinical relevance, openness, and international growth, Great Robotics is showing what’s possible when deep tech meets deep purpose.

April 28, 2025, By MedChina